AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Cancer Biology & Medicine Article
PDF (1 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Review | Open Access

Research progress in hepatitis B virus covalently closed circular DNA

Xiaodong Zhang1 ( ), Yufei Wang2, Guang Yang1
Department of Gastrointestinal Cancer Biology, Liver Cancer Center, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, China
Department of Cancer Research, College of Life Sciences, Nankai University, Tianjin 300071, China
Show Author Information

Abstract

Hepatitis B virus (HBV) infections are a global public health issue. HBV covalently closed circular DNA (cccDNA), the template for the transcription of viral RNAs, is a key factor in the HBV replication cycle. Notably, many host factors involved in HBV cccDNA epigenetic modulation promote the development of hepatocellular carcinoma (HCC). The HBV cccDNA minichromosome is a clinical obstacle that cannot be efficiently eliminated. In this review, we provide an update on the advances in research on HBV cccDNA and further discuss factors affecting the modulation of HBV cccDNA. Hepatitis B virus X protein (HBx) contributes to HBV cccDNA transcription and the development of hepatocarcinogenesis through modulating host epigenetic regulatory factors, thus linking the cccDNA to hepatocarcinogenesis. The measurable serological biomarkers of continued transcription of cccDNA, the effects of anti-HBV drugs on cccDNA, and potential therapeutic strategies targeting cccDNA are discussed in detail. Thus, this review describes new insights into HBV cccDNA mechanisms and therapeutic strategies for cleaning cccDNA, which will benefit patients with liver diseases.

Keywords

therapyHepatitis B viruscccDNAHBxhepatocarcinogenesisepigenetic modulation

References

1

Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 2014; 343: 1221-8.
Crossref Google Scholar
2

Koniger C, Wingert I, Marsmann M, Rosler C, Beck J, Nassal M. Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses. Proc Natl Acad Sci U S A. 2014; 111: E4244-53.
Crossref Google Scholar
3

Luo X, Huang Y, Chen Y, Tu Z, Hu J, Tavis JE, et al. Association of hepatitis B virus covalently closed circular DNA and human APOBEC3B in hepatitis B virus-related hepatocellular carcinoma. PLoS One. 2016; 11: e0157708-22.
Crossref Google Scholar
4

Hu J, Protzer U, Siddiqui A. Revisiting hepatitis B virus: challenges of curative therapies. J Virol. 2019; 93: e01032-19.
Crossref Google Scholar
5

Tropberger P, Mercier A, Robinson M, Zhong W, Ganem DE, Holdorf M. Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation. Proc Natl Acad Sci U S A. 2015; 112: E5715-24.
Crossref Google Scholar
6

Li X, Zhao J, Yuan Q, Xia N. Detection of HBV covalently closed circular DNA. Viruses. 2017; 9: 139-57.
Crossref Google Scholar
7

Gao W, Hu J. Formation of hepatitis B virus covalently closed circular DNA: removal of genome-linked protein. J Virol. 2007; 81: 6164-74.
Crossref Google Scholar
8

Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol. 2009; 51: 581-92.
Crossref Google Scholar
9

Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016; 64: S84-101.
Crossref Google Scholar
10

Schwabe RF, Greten TF. Gut microbiome in HCC–mechanisms, diagnosis and therapy. J Hepatol. 2020; 72: 230-8.
Crossref Google Scholar
11

Di Bisceglie AM. Hepatitis B and hepatocellular carcinoma. Hepatology. 2009; 49: S56-60.
Crossref Google Scholar
12

Chen Y, Tian Z. HBV-induced immune imbalance in the development of HCC. Front Immunol. 2019; 10: 2048-58.
Crossref Google Scholar
13

Zhang C, Huang C, Sui X, Zhong X, Yang W, Hu X, et al. Association between gene methylation and HBV infection in hepatocellular carcinoma: a meta-analysis. J Cancer. 2019; 10: 6457-65.
Crossref Google Scholar
14

Xu C, Zhou W, Wang Y, Qiao L. Hepatitis B virus-induced hepatocellular carcinoma. Cancer Lett. 2014; 345: 216-22.
Crossref Google Scholar
15

Jia L, Gao Y, He Y, Hooper JD, Yang P. HBV induced hepatocellular carcinoma and related potential immunotherapy. Pharmacol Res. 2020; 159: 104992-7.
Crossref Google Scholar
16

Zhang WY, Cai N, Ye LH, Zhang XD. Transformation of human liver L-O2 cells mediated by stable HBx transfection. Acta Pharmacol Sin. 2009; 30: 1153-61.
Crossref Google Scholar
17

Zhang X, You X, Li N, Zhang W, Gagos S, Wang Q, et al. Involvement of hepatitis B virus X gene (HBx) integration in hepatocarcinogenesis via a recombination of HBx/Alu core sequence/subtelomeric DNA. FEBS Lett. 2012; 586: 3215-21.
Crossref Google Scholar
18

Wang H, Liu Y, Wang D, Xu Y, Dong R, Yang Y, et al. The upstream pathway of mTOR-mediated autophagy in liver diseases. Cells. 2019; 8: 1597-632.
Crossref Google Scholar
19

Lu X, Paliogiannis P, Calvisi DF, Chen X. Role of the mammalian target of rapamycin pathway in liver cancer: From molecular genetics to targeted therapies. Hepatology. 2021; 73 Suppl 1: 49-61.
Crossref Google Scholar
20

Zheng YL, Li L, Jia YX, Zhang BZ, Li JC, Zhu YH, et al. LINC01554-mediated glucose metabolism reprogramming suppresses tumorigenicity in hepatocellular carcinoma via downregulating PKM2 expression and inhibiting Akt/mTOR signaling pathway. Theranostics. 2019; 9: 796-810.
Crossref Google Scholar
21

Allweiss L, Dandri M. The role of cccDNA in HBV maintenance. Viruses. 2017; 9: 156-67.
Crossref Google Scholar
22

Newbold JE, Xin H, Tencza M, Sherman G, Dean J, Bowden S, et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol. 1995; 69: 3350-7.
Crossref Google Scholar
23

Bock CT, Schranz P, Schroder CH, Zentgraf H. Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell. Virus Genes. 1994; 8: 215-29.
Crossref Google Scholar
24

Bock CT, Schwinn S, Locarnini S, Fyfe J, Manns MP, Trautwein C, et al. Structural organization of the hepatitis B virus minichromosome. J Mol Biol. 2001; 307: 183-96.
Crossref Google Scholar
25

Belloni L, Pollicino T, De Nicola F, Guerrieri F, Raffa G, Fanciulli M, et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci U S A. 2009; 106: 19975-9.
Crossref Google Scholar
26

Lucifora J, Arzberger S, Durantel D, Belloni L, Strubin M, Levrero M, et al. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol. 2011; 55: 996-1003.
Crossref Google Scholar
27

Lee H, Jeong H, Lee SY, Kim SS, Jang KL. Hepatitis B virus X protein stimulates virus replication via DNA methylation of the C-1619 in covalently closed circular DNA. Mol Cells. 2019; 42: 67-78.
Google Scholar
28

Chong CK, Cheng CYS, Tsoi SYJ, Huang FY, Liu F, Fung J, et al. HBV X protein mutations affect HBV transcription and association of histone-modifying enzymes with covalently closed circular DNA. Sci Rep. 2020; 10: 802-11.
Crossref Google Scholar
29

Saeed U, Kim J, Piracha ZZ, Kwon H, Jung J, Chwae YJ, et al. Parvulin 14 and parvulin 17 bind to HBx and cccDNA and upregulate hepatitis B virus replication from cccDNA to virion in an HBx-dependent manner. J Virol. 2019; 93: e01840-18.
Crossref Google Scholar
30

Kinoshita W, Ogura N, Watashi K, Wakita T. Host factor PRPF31 is involved in cccDNA production in HBV-replicating cells. Biochem Biophys Res Commun. 2017; 482: 638-44.
Crossref Google Scholar
31

Decorsiere A, Mueller H, van Breugel PC, Abdul F, Gerossier L, Beran RK, et al. Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor. Nature. 2016; 531: 386-9.
Crossref Google Scholar
32

Riviere L, Gerossier L, Ducroux A, Dion S, Deng Q, Michel ML, et al. HBx relieves chromatin-mediated transcriptional repression of hepatitis B viral cccDNA involving SETDB1 histone methyltransferase. J Hepatol. 2015; 63: 1093-102.
Crossref Google Scholar
33

Cheng J, Zhao Q, Zhou Y, Tang L, Sheraz M, Chang J, et al. Interferon alpha induces multiple cellular proteins that coordinately suppress hepadnaviral covalently closed circular DNA transcription. J Virol. 2020; 94-115.
Crossref Google Scholar
34

Yang Y, Zhao X, Wang Z, Shu W, Li L, Li Y, et al. Nuclear sensor interferon-inducible protein 16 inhibits the function of hepatitis B virus covalently closed circular DNA by integrating innate immune activation and epigenetic suppression. Hepatology. 2020; 71: 1154-69.
Crossref Google Scholar
35

Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, et al. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest. 2012; 122: 529-37.
Crossref Google Scholar
36

Benhenda S, Ducroux A, Riviere L, Sobhian B, Ward MD, Dion S, et al. Methyltransferase PRMT1 is a binding partner of HBx and a negative regulator of hepatitis B virus transcription. J Virol. 2013; 87: 4360-71.
Crossref Google Scholar
37

Salerno D, Chiodo L, Alfano V, Floriot O, Cottone G, Paturel A, et al. Hepatitis B protein HBx binds the DLEU2 lncRNA to sustain cccDNA and host cancer-related gene transcription. Gut. 2020; 69: 2016-24.
Crossref Google Scholar
38

Yang G, Feng J, Liu Y, Zhao M, Yuan Y, Yuan H, et al. HAT1 signaling confers to assembly and epigenetic regulation of HBV cccDNA minichromosome. Theranostics. 2019; 9: 7345-58.
Crossref Google Scholar
39

Feng J, Yang G, Liu Y, Gao Y, Zhao M, Bu Y, et al. LncRNA PCNAP1 modulates hepatitis B virus replication and enhances tumor growth of liver cancer. Theranostics. 2019; 9: 5227-45.
Crossref Google Scholar
40

Hong X, Kim ES, Guo H. Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B. Hepatology. 2017; 66: 2066-77.
Crossref Google Scholar
41

Liu K, Ludgate L, Yuan Z, Hu J. Regulation of multiple stages of hepadnavirus replication by the carboxyl-terminal domain of viral core protein in trans. J Virol. 2015; 89: 2918-30.
Crossref Google Scholar
42

Cui X, Luckenbaugh L, Bruss V, Hu J. Alteration of mature nucleocapsid and enhancement of covalently closed circular DNA formation by hepatitis B virus core mutants defective in completevirion formation. J Virol. 2015; 89: 10064-72.
Crossref Google Scholar
43

Guo H, Mao R, Block TM, Guo JT. Production and function of the cytoplasmic deproteinized relaxed circular DNA of hepadnaviruses. J Virol. 2010; 84: 387-96.
Crossref Google Scholar
44

Luo J, Luckenbaugh L, Hu H, Yan Z, Gao L, Hu J. Involvement of host ATR-CHK1 pathway in hepatitis B virus covalently closed circular DNA formation. mBio. 2020; 11: e03423-19.
Crossref Google Scholar
45

Wing PA, Davenne T, Wettengel J, Lai AG, Zhuang X, Chakraborty A, et al. A dual role for SAMHD1 in regulating HBV cccDNA and RT-dependent particle genesis. Life Sci Alliance. 2019; 2: e201900355-66.
Crossref Google Scholar
46

Sheraz M, Cheng J, Tang L, Chang J, Guo JT. Cellular DNA topoisomerases are required for the synthesis of hepatitis B virus covalently closed circular DNA. J Virol. 2019; 93: e02230-18.
Crossref Google Scholar
47

Kitamura K, Que L, Shimadu M, Koura M, Ishihara Y, Wakae K, et al. Flap endonuclease 1 is involved in cccDNA formation in the hepatitis B virus. PLoS Pathog. 2018; 14: e1007124-43.
Crossref Google Scholar
48

Qi Y, Gao Z, Xu G, Peng B, Liu C, Yan H, et al. DNA Polymerase kappa is a key cellular factor for the formation of covalently closed circular DNA of hepatitis B virus. PLoS Pathog. 2016; 12: e1005893-918.
Crossref Google Scholar
49

Tang L, Sheraz M, McGrane M, Chang J, Guo JT. DNA Polymerase alpha is essential for intracellular amplification of hepatitis B virus covalently closed circular DNA. PLoS Pathog. 2019; 15: e1007742-69.
Crossref Google Scholar
50

Long Q, Yan R, Hu J, Cai D, Mitra B, Kim ES, et al. The role of host DNA ligases in hepadnavirus covalently closed circular DNA formation. PLoS Pathog. 2017; 13: e1006784.
Crossref Google Scholar
51

Wei L, Ploss A. Core components of DNA lagging strand synthesis machinery are essential for hepatitis B virus cccDNA formation. Nat Microbiol. 2020; 5: 715-26.
Crossref Google Scholar
52

Brezgin S, Kostyusheva A, Bayurova E, Gordeychuk I, Isaguliants M, Goptar I, et al. Replenishment of hepatitis B virus cccDNA pool is restricted by baseline expression of host restriction factors in vitro. Microorganisms. 2019; 7: 533-48.
Crossref Google Scholar
53

Zhou L, Ren JH, Cheng ST, Xu HM, Chen WX, Chen DP, et al. A Functional variant in ubiquitin conjugating enzyme E2 L3 contributes to hepatitis B virus infection and maintains covalently closed circular DNA stability by inducing degradation of apolipoprotein B mRNA editing enzyme catalytic subunit 3A. Hepatology. 2019; 69: 1885-902.
Crossref Google Scholar
54

Liu Z, Wang J, Yuan H, Liu L, Bu Y, Zhao M, et al. IFN-alpha2b inhibits the ethanol enriched-HBV cccDNA through blocking a positive feedback loop of HBx/MSL2/cccDNA/HBV/HBx in liver. Biochem Biophys Res Commun. 2020; 527: 76-82.
Crossref Google Scholar
55

Gao Y, Feng J, Yang G, Zhang S, Liu Y, Bu Y, et al. Hepatitis B virus X protein-elevated MSL2 modulates hepatitis B virus covalently closed circular DNA by inducing degradation of APOBEC3B to enhance hepatocarcinogenesis. Hepatology. 2017; 66: 1413-29.
Crossref Google Scholar
56

Liu Y, Feng J, Sun M, Yang G, Yuan H, Wang Y, et al. Long noncoding RNA HULC activates HBV by modulating HBx/STAT3/miR-539/APOBEC3B signaling in HBV-related hepatocellular carcinoma. Cancer Lett. 2019; 454: 158-70.
Crossref Google Scholar
57

Wang YX, Niklasch M, Liu T, Wang Y, Shi B, Yuan W, et al. Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication. J Hepatol. 2020; 72: 865-76.
Crossref Google Scholar
58

Flecken T, Meier MA, Skewes-Cox P, Barkan DT, Heim MH, Wieland SF, et al. Mapping the heterogeneity of Histone modifications on hepatitis B virus DNA using liver needle biopsies obtained from chronically infected patients. J Virol. 2019; 93: e02036-18.
Crossref Google Scholar
59

Ren JH, Hu JL, Cheng ST, Yu HB, Wong VKW, Law BYK, et al. SIRT3 restricts hepatitis B virus transcription and replication through epigenetic regulation of covalently closed circular DNA involving suppressor of variegation 3-9 homolog 1 and SET domain containing 1A histone methyltransferases. Hepatology. 2018; 68: 1260-76.
Crossref Google Scholar
60

Guerrieri F, Belloni L, D’Andrea D, Pediconi N, Le Pera L, Testoni B, et al. Genome-wide identification of direct HBx genomic targets. BMC Genomics. 2017; 18: 184.
Crossref Google Scholar
61

Slagle BL, Bouchard MJ. Hepatitis B virus X and regulation of viral gene expression. Cold Spring Harb Perspect Med. 2016; 6: a021402.
Crossref Google Scholar
62

Guo YH, Li YN, Zhao JR, Zhang J, Yan Z. HBc binds to the CpG islands of HBV cccDNA and promotes an epigenetic permissive state. Epigenetics. 2011; 6: 720-6.
Crossref Google Scholar
63

Zhang Y, Mao R, Yan R, Cai D, Zhang Y, Zhu H, et al. Transcription of hepatitis B virus covalently closed circular DNA is regulated by CpG methylation during chronic infection. PLoS One. 2014; 9: e110442.
Crossref Google Scholar
64

Jain S, Chang TT, Chen S, Boldbaatar B, Clemens A, Lin SY, et al. Comprehensive DNA methylation analysis of hepatitis B virus genome in infected liver tissues. Sci Rep. 2015; 5: 10478-88.
Crossref Google Scholar
65

Chong CK, Cheng CYS, Tsoi SYJ, Huang FY, Liu F, Seto WK, et al. Role of hepatitis B core protein in HBV transcription and recruitment of histone acetyltransferases to cccDNA minichromosome. Antiviral Res. 2017; 144: 1-7.
Crossref Google Scholar
66

Lucifora J, Pastor F, Charles É, Pons C, Auclair H, Fusil F, et al. Evidence for long-term association of virion-delivered HBV core protein with cccDNA independently of viral protein production. JHEP reports: innovation in hepatology. 2021; 3: 100330-5.
Crossref Google Scholar
67

Wang Z, Kawaguchi K, Honda M, Hashimoto S, Shirasaki T, Okada H, et al. Notch signaling facilitates hepatitis B virus covalently closed circular DNA transcription via cAMP response elementbinding protein with E3 ubiquitin ligase-modulation. Sci Rep. 2019; 9: 1621-2.
Crossref Google Scholar
68

Zeng J, Wu D, Hu H, Young JAT, Yan Z, Gao L. Activation of the liver X receptor pathway inhibits HBV replication in primary human Hepatocytes. Hepatology. 2020; 72: 1935-48.
Crossref Google Scholar
69

Yuan Y, Zhao K, Yao Y, Liu C, Chen Y, Li J, et al. HDAC11 restricts HBV replication through epigenetic repression of cccDNA transcription. Antiviral Res. 2019; 172: 104619-27.
Crossref Google Scholar
70

Zhang W, Chen J, Wu M, Zhang X, Zhang M, Yue L, et al. PRMT5 restricts hepatitis B virus replication through epigenetic repression of covalently closed circular DNA transcription and interference with pregenomic RNA encapsidation. Hepatology. 2017; 66: 398-415.
Crossref Google Scholar
71

Sekiba K, Otsuka M, Ohno M, Yamagami M, Kishikawa T, Seimiya T, et al. Pevonedistat, a neuronal precursor cell-expressed developmentally down-regulated protein 8-activating enzyme inhibitor, is a potent inhibitor of hepatitis B virus. Hepatology. 2019; 69: 1903-15.
Crossref Google Scholar
72

Liu N, Zhang J, Yang X, Jiao T, Zhao X, Li W, et al. HDM2 promotes NEDDylation of hepatitis B virus HBx to enhance its stability and function. J Virol. 2017; 91: e00340-17.
Crossref Google Scholar
73

Han S, Shin H, Oh JW, Oh YJ, Her NG, Nam DH. The protein neddylation inhibitor MLN4924 suppresses patient-derived glioblastoma cells via inhibition of ERK and AKT signaling. Cancers. 2019; 11: 1849-63.
Crossref Google Scholar
74

Zhang H, Xing Z, Mani SK, Bancel B, Durantel D, Zoulim F, et al. RNA helicase DEAD box protein 5 regulates Polycomb repressive complex 2/Hox transcript antisense intergenic RNA function in hepatitis B virus infection and hepatocarcinogenesis. Hepatology. 2016; 64: 1033-48.
Crossref Google Scholar
75

Moon IY, Choi JH, Chung JW, Jang ES, Jeong SH, Kim JW. MicroRNA20 induces methylation of hepatitis B virus covalently closed circular DNA in human hepatoma cells. Mol Med Rep. 2019; 20: 2285-93.
Crossref Google Scholar
76

Xing T, Zhu J, Xian J, Li A, Wang X, Wang W, et al. miRNA-548ah promotes the replication and expression of hepatitis B virus by targeting histone deacetylase 4. Life Sci. 2019; 219: 199-208.
Crossref Google Scholar
77

Xia Y, Guo H. Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential. Antiviral Res. 2020; 180: 104824.
Crossref Google Scholar
78

Hamada-Tsutsumi S, Naito Y, Sato S, Takaoka A, Kawashima K, Isogawa M, et al. The antiviral effects of human microRNA miR-302c-3p against hepatitis B virus infection. Aliment Pharmacol Ther. 2019; 49: 1060-70.
Crossref Google Scholar
79

Bai F, Yano Y, Fukumoto T, Takebe A, Tanaka M, Kuramitsu K, et al. Quantification of pregenomic RNA and covalently closed circular DNA in hepatitis B virus-related hepatocellular carcinoma. Int J Hepatol. 2013; 2013: 849290-8.
Crossref Google Scholar
80

Meng C, Liu T, Liu YW, Zhang LZ, Wang YL. Hepatitis B virus cccDNA in hepatocellular carcinoma tissue increases the risk of recurrence after liver transplantation. Transplant Proc. 2019; 51: 3364-8.
Crossref Google Scholar
81

Gao J, Xiong Y, Wang Y, Wang Y, Zheng G, Xu H. Hepatitis B virus X protein activates Notch signaling by its effects on Notch1 and Notch4 in human hepatocellular carcinoma. Int J Oncol. 2016; 48: 329-37.
Crossref Google Scholar
82

Jin XL, Hong SK, Kim H, Lee SK, Yi NJ, Lee KW, et al. Antiviral therapy may decrease HBx, affecting cccDNA and MSL2 in hepatocarcinogenesis. Oncol Lett. 2019; 18: 4984-91.
Crossref Google Scholar
83

Moyo B, Nicholson SA, Arbuthnot PB. The role of long non-coding RNAs in hepatitis B virus-related hepatocellular carcinoma. Virus Res. 2016; 212: 103-13.
Crossref Google Scholar
84

Cai D, Nie H, Yan R, Guo JT, Block TM, Guo H. A southern blot assay for detection of hepatitis B virus covalently closed circular DNA from cell cultures. Methods Mol Biol. 2013; 1030: 151-61.
Crossref Google Scholar
85

Mazet-Wagner AA, Baclet MC, Loustaud-Ratti V, Denis F, Alain S. Real-time PCR quantitation of hepatitis B virus total DNA and covalently closed circular DNA in peripheral blood mononuclear cells from hepatitis B virus-infected patients. J Virol Methods. 2006; 138: 70-9.
Crossref Google Scholar
86

Xu CH, Li ZS, Dai JY, Zhu HY, Yu JW, Lu SL. Nested real-time quantitative polymerase chain reaction assay for detection of hepatitis B virus covalently closed circular DNA. Chin Med J (Engl). 2011; 124: 1513-6.
Google Scholar
87

Takkenberg RB, Zaaijer HL, Menting S, Weegink CJ, Terpstra V, Cornelissen M, et al. Detection of hepatitis B virus covalently closed circular DNA in paraffin-embedded and cryo-preserved liver biopsies of chronic hepatitis B patients. Eur J Gastroenterol Hepatol. 2010; 22: 952-60.
Crossref Google Scholar
88

Zhong Y, Hu S, Xu C, Zhao Y, Xu D, Zhao Y, et al. A novel method for detection of HBVcccDNA in hepatocytes using rolling circle amplification combined with in situ PCR. BMC Infect Dis. 2014; 14: 608-15.
Crossref Google Scholar
89

Guo Y, Sheng S, Nie B, Tu Z. Development of magnetic capture hybridization and quantitative polymerase chain reaction for hepatitis B virus covalently closed circular DNA. Hepat Mon. 2015; 15: e23729.
Crossref Google Scholar
90

Jiang PX, Mao RC, Dong MH, Yu XP, Xun Q, Wang JY, et al. Exonuclease I and Ⅲ improve the detection efficacy of hepatitis B virus covalently closed circular DNA. Hepatobiliary Pancreat Dis Int. 2019; 18: 458-63.
Crossref Google Scholar
91

Mu D, Yan L, Tang H, Liao Y. A sensitive and accurate quantification method for the detection of hepatitis B virus covalently closed circular DNA by the application of a droplet digital polymerase chain reaction amplification system. Biotechnol Lett. 2015; 37: 2063-73.
Crossref Google Scholar
92

Caviglia GP, Abate ML, TandoiF, Ciancio A, Amoroso A, Salizzoni M, et al. Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection. J Hepatol. 2018; 69: 301-7.
Crossref Google Scholar
93

Huang JT, Yang Y, Hu YM, Liu XH, Liao MY, Morgan R, et al. A highly sensitive and robust method for hepatitis B virus covalently closed circular DNA detection in single cells and serum. J Mol Diagn. 2018; 20: 334-43.
Crossref Google Scholar
94

Zhang X, Lu W, Zheng Y, Wang W, Bai L, Chen L, et al. In situ analysis of intrahepatic virological events in chronic hepatitis B virus infection. J Clin Invest. 2016; 126: 1079-92.
Crossref Google Scholar
95

European association for the study of the liver. Electronic address EEE, European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017; 67: 370-98.
Crossref Google Scholar
96

Tu T, Zehnder B, Qu B, Ni Y, Main N, Allweiss L, et al. A novel method to precisely quantify hepatitis B virus covalently closed circular (ccc)DNA formation and maintenance. Antiviral Res. 2020; 181: 104865-74.
Crossref Google Scholar
97

Gao Y, Li Y, Meng Q, Zhang Z, Zhao P, Shang Q, et al. Serum hepatitis B virus DNA, RNA, and HBsAg: Which correlated better with intrahepatic covalently closed circular DNA before and after nucleos(t)ide analogue treatment? J Clin Microbiol. 2017; 55: 2972-82.
Crossref Google Scholar
98

Liu Y, Jiang M, Xue J, Yan H, Liang X. Serum HBV RNA quantification: useful for monitoring natural history of chronic hepatitis B infection. BMC Gastroenterol. 2019; 19: 53-61.
Crossref Google Scholar
99

Huang Q, Zhou B, Cai D, Zong Y, Wu Y, Liu S, et al. Rapid turnover of hepatitis B virus covalently closed circular DNA Indicated by monitoring emergence and reversion of signaturemutation in treated chronic hepatitis B patients. Hepatology. 2021; 73: 41-52.
Crossref Google Scholar
100

Limothai U, Chuaypen N, Poovorawan K, Chotiyaputta W, Tanwandee T, Poovorawan Y, et al. Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferonbased therapy in patients with hepatitis B e antigen-negative chronic hepatitis B. J Viral Hepat. 2019; 26: 1481-8.
Crossref Google Scholar
101

van Campenhout MJH, van Bommel F, Pfefferkorn M, Fischer J, Deichsel D, Boonstra A, et al. Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B. J Viral Hepat. 2020; 27: 610-9.
Crossref Google Scholar
102

Wang J, Yu Y, Li G, Shen C, Meng Z, Zheng J, et al. Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients. J Hepatol. 2018; 68: 16-24.
Crossref Google Scholar
103

Wang J, Shen T, Huang X, Kumar GR, Chen X, Zeng Z, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol. 2016; 65: 700-10.
Crossref Google Scholar
104

Huang H, Wang J, Li W, Chen R, Chen X, Zhang F, et al. Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naive HBV-infected individuals. J Clin Virol. 2018; 99-100: 71-8.
Crossref Google Scholar
105

Bai L, Zhang X, Kozlowski M, Li W, Wu M, Liu J, et al. Extracellular hepatitis B virus RNAs are heterogeneous in length and circulate as capsid-antibody complexes in addition to virions in chronic hepatitis B patients. J Virol. 2018; 92: e00798-18.
Crossref Google Scholar
106

Shen S, Xie Z, Cai D, Yu X, Zhang H, Kim ES, et al. Biogenesis and molecular characteristics of serum hepatitis B virus RNA. PLoS Pathog. 2020; 16: e1008945.
Crossref Google Scholar
107

Kimura T, Rokuhara A, Sakamoto Y, Yagi S, Tanaka E, Kiyosawa K, et al. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J Clin Microbiol. 2002; 40: 439-45.
Crossref Google Scholar
108

Kimura T, Ohno N, Terada N, Rokuhara A, Matsumoto A, Yagi S, et al. Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain. J Biol Chem. 2005; 280: 21713-9.
Crossref Google Scholar
109

Rokuhara A, Tanaka E, Matsumoto A, Kimura T, Yamaura T, Orii K, et al. Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment. J Viral Hepat. 2003; 10: 324-30.
Crossref Google Scholar
110

Chen EQ, Feng S, Wang ML, Liang LB, Zhou LY, Du LY, et al. Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B. Sci Rep. 2017; 7: 173-80.
Crossref Google Scholar
111

Wang L, Cao X, Wang Z, Gao Y, Deng J, Liu X, et al. Correlation of HBcrAg with intrahepatic hepatitis B virus total DNA and covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients. J Clin Microbiol. 2019; 57: e01303-18.
Crossref Google Scholar
112

Matsuzaki T, Tatsuki I, Otani M, Akiyama M, Ozawa E, Miuma S, et al. Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation. J Gastroenterol Hepatol. 2013; 28: 1217-22.
Crossref Google Scholar
113

Wong DK, Seto WK, Cheung KS, Chong CK, Huang FY, Fung J, et al. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. Liver Int. 2017; 37: 995-1001.
Crossref Google Scholar
114

Testoni B, Lebosse F, Scholtes C, Berby F, Miaglia C, Subic M, et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J Hepatol. 2019; 70: 615-25.
Crossref Google Scholar
115

Chen EQ, Wang ML, Tao YC, Wu DB, Liao J, He M, et al. Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA. J Viral Hepat. 2019; 26: 586-95.
Crossref Google Scholar
116

van Campenhout MJH, Rijckborst V, Brouwer WP, van Oord GW, Ferenci P, Tabak F, et al. Hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAgnegative chronic hepatitis B. J Viral Hepat. 2019; 26: 1156-63.
Crossref Google Scholar
117

Yuan Y, Yuan H, Yang G, Yun H, Zhao M, Liu Z, et al. IFN-alpha confers epigenetic regulation of HBV cccDNA minichromosome by modulating GCN5-mediated succinylation of histone H3K79 to clear HBV cccDNA. Clin Epigenetics. 2020; 12: 135.
Crossref Google Scholar
118

Liu F, Campagna M, Qi Y, Zhao X, Guo F, Xu C, et al. Alphainterferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog. 2013; 9: e1003613.
Crossref Google Scholar
119

Furutani Y, Toguchi M, Shiozaki-Sato Y, Qin XY, Ebisui E, Higuchi S, et al. An interferon-like small chemical compound CDM-3008 suppresses hepatitis B virus through induction of interferonstimulated genes. PLoS One. 2019; 14: e0216139.
Crossref Google Scholar
120

Bockmann JH, Stadler D, Xia Y, Ko C, Wettengel JM, Schulze Zur Wiesch J, et al. Comparative analysis of the antiviral effects mediated by type Ⅰ and Ⅲ interferons in hepatitis B virus-infected hepatocytes. J Infect Dis. 2019; 220: 567-77.
Crossref Google Scholar
121

Xia Y, Stadler D, Lucifora J, Reisinger F, Webb D, Hösel M, et al. Interferon-γ and tumor necrosis factor-α produced by T cells reduce the HBV persistence form, cccDNA, without cytolysis. Gastroenterology. 2016; 150: 194-205.
Crossref Google Scholar
122

Qiao Y, Han X, Guan G, Wu N, Sun J, Pak V, et al. TGF-beta triggers HBV cccDNA degradation through AID-dependent deamination. FEBS Lett. 2016; 590: 419-27.
Crossref Google Scholar
123

Shi A, Zhang X, Xiao F, Zhu L, Yan W, Han M, et al. CD56(bright) natural killer cells induce HBsAg reduction via cytolysis and cccDNA decay in long-term entecavir-treated patients switching to peginterferon alfa-2a. J Viral Hepat. 2018; 25: 1352-62.
Crossref Google Scholar
124

Shen Z, Liu J, Wu J, Zhu Y, Li G, Wang J, et al. IL-21-based therapies induce clearance of hepatitis B virus persistence in mouse models. Theranostics. 2019; 9: 3798-811.
Crossref Google Scholar
125

Palumbo GA, Scisciani C, Pediconi N, Lupacchini L, Alfalate D, Guerrieri F, et al. IL6 inhibits HBV transcription by targeting the epigenetic control of the nuclear cccDNA minichromosome. PLoS One. 2015; 10: e0142599.
Crossref Google Scholar
126

Cai D, Mills C, Yu W, Yan R, Aldrich CE, Saputelli JR, et al. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother. 2012; 56: 4277-88.
Crossref Google Scholar
127

Fanning GC, Zoulim F, Hou J, Bertoletti A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov. 2019; 18: 827-44.
Crossref Google Scholar
128

Amblard F, Boucle S, Bassit L, Cox B, Sari O, Tao S, et al. Novel hepatitis B virus capsid assembly modulator induces potent antiviral responses in vitro and in humanized mice. Antimicrob Agents Chemother. 2020; 64: e01701-19.
Crossref Google Scholar
129

Ko C, Bester R, Zhou X, Xu Z, Blossey C, Sacherl J, et al. A new role for capsid assembly modulators to target mature hepatitis B virus capsids and prevent virus infection. Antimicrob Agents Chemother. 2019; 64: e01440-19.
Crossref Google Scholar
130

Liu C, Cai D, Zhang L, Tang W, Yan R, Guo H, et al. Identification of hydrolyzable tannins (punicalagin, punicalin and geraniin) as novel inhibitors of hepatitis B virus covalently closed circular DNA. Antiviral Res. 2016; 134: 97-107.
Crossref Google Scholar
131

Sekiba K, Otsuka M, Ohno M, Yamagami M, Kishikawa T, Suzuki T, et al. Inhibition of HBV transcription from cccDNA with nitazoxanide by targeting the HBx-DDB1 interaction. Cell Mol Gastroenterol Hepatol. 2019; 7: 297-312.
Crossref Google Scholar
132

Cheng ST, Hu JL, Ren JH, Yu HB, Zhong S, Wai Wong VK, et al. Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx. J Hepatol. 2021; 74: 522-34.
Crossref Google Scholar
133

Wei ZQ, Zhang YH, Ke CZ, Chen HX, Ren P, He YL, et al. Curcumin inhibits hepatitis B virus infection by down-regulating cccDNAbound histone acetylation. World J Gastroenterol. 2017; 23: 6252-60.
Crossref Google Scholar
134

Nkongolo S, Nussbaum L, Lempp FA, Wodrich H, Urban S, Ni Y. The retinoic acid receptor (RAR) alpha-specific agonist Am80 (tamibarotene) and other RAR agonists potently inhibit hepatitis B virus transcription from cccDNA. Antiviral Res. 2019; 168: 146-55.
Crossref Google Scholar
135

Cradick TJ, Keck K, Bradshaw S, Jamieson AC, McCaffrey AP. Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol Ther. 2010; 18: 947-54.
Crossref Google Scholar
136

Schiffer JT, Swan DA, Stone D, Jerome KR. Predictors of hepatitis B cure using gene therapy to deliver DNA cleavage enzymes: a mathematical modeling approach. PLoS Comput Biol. 2013; 9: e1003131.
Crossref Google Scholar
137

Teng Y, Xu Z, Zhao K, Zhong Y, Wang J, Zhao L, et al. Novel function of SART1 in HNF4α transcriptional regulation contributes to its antiviral role during HBV infection. J Hepatol. 2021; 75: 1072-82.
Crossref Google Scholar
138

Kennedy EM, Bassit LC, Mueller H, Kornepati AVR, Bogerd HP, Nie T, et al. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology. 2015; 476: 196-205.
Crossref Google Scholar
139

Schiwon M, Ehrke-Schulz E, Oswald A, Bergmann T, Michler T, Protzer U, et al. One-vector system for multiplexed CRISPR/Cas9 against hepatitis B virus cccDNA utilizing highcapacity adenoviral vectors. Mol Ther Nucleic Acids. 2018; 12: 242-53.
Crossref Google Scholar
140

Kostyushev D, Brezgin S, Kostyusheva A, Zarifyan D, Goptar I, Chulanov V. Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus. Cell Mol Life Sci. 2019; 76: 1779-94.
Crossref Google Scholar
141

Seeger C, Sohn JA. Complete spectrum of CRISPR/Cas9-induced mutations on HBV cccDNA. Mol Ther. 2016; 24: 1258-66.
Crossref Google Scholar
142

Zhu Y, Yamamoto T, Cullen J, Saputelli J, Aldrich CE, Miller DS, et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol. 2001; 75: 311-22.
Crossref Google Scholar
143

van den Berg F, Limani SW, Mnyandu N, Maepa MB, Ely A, Arbuthnot P. Advances with RNAi-based therapy for hepatitis B virus infection. Viruses. 2020; 12; 851-70.
Crossref Google Scholar
144

Wang J, Chen R, Zhang R, Ding S, Zhang T, Yuan Q, et al. The gRNA-miRNA-gRNA ternary cassette combining CRISPR/Cas9 with RNAi approach strongly inhibits hepatitis B virus replication. Theranostics. 2017; 7: 3090-105.
Crossref Google Scholar
145

Lutgehetmann M, Volz T, Kopke A, Broja T, Tigges E, Lohse AW, et al. In vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice. Hepatology. 2010; 52: 16-24.
Crossref Google Scholar
146

Allweiss L, Volz T, Giersch K, Kah J, Raffa G, Petersen J, et al. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo. Gut. 2018; 67: 542-52.
Crossref Google Scholar
147

Petersen J, Thompson AJ, Levrero M. Aiming for cure in HBV and HDV infection. J Hepatol. 2016; 65: 835-48.
Crossref Google Scholar
148

Dandri M, Lutgehetmann M. Mouse models of hepatitis B and delta virus infection. J Immunol Methods. 2014; 410: 39-49.
Crossref Google Scholar
Cancer Biology & Medicine
Volume 19 Issue 4,
April 2022
Pages 415-431
DOI: 10.20892/j.issn.2095-3941.2021.0454
Cite this article:
Zhang X, Wang Y, Yang G. Research progress in hepatitis B virus covalently closed circular DNA. Cancer Biology & Medicine, 2022, 19(4): 415-431. https://doi.org/10.20892/j.issn.2095-3941.2021.0454

142

Views

3

Downloads

7

Crossref

8

Web of Science

9

Scopus

Altmetrics
Received: 26 August 2021
Accepted: 16 November 2021
Published: 01 April 2022
©2022 Cancer Biology & Medicine.

Creative Commons Attribution-NonCommercial 4.0 International License
Return